Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | MGAM | O43451 | 6/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scyllitol SCHEMBL12411898 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL6378921 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL4447990 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL4438767 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12377889 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL21388397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL5969 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL959405 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL188106 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| SCHEMBL1963355 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250414-A1 | STABILISED, TRANSITION-METAL-CONTAINING PLASTICS COMPOSITIONS, MOULDING COMPOUND OR MOULDED PART AND USE OF A STABILISER COMPOSITION FOR STABILISING TRANSITION METAL-CONTAINING PLASTICS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-08-07 | — | — | US | claimed |
| EP-4516303-A1 | COMPOSITION INCLUDING TEUPOLIOSIDE AND INOSITOL | IDI Integratori Dietetici Italiani S.r.l. (IT) | 2025-03-05 | — | — | EP | claimed |
| EP-4508127-A1 | STABILISED, TRANSITION-METAL-CONTAINING PLASTICS COMPOSITIONS, MOULDING COMPOUND OR MOULDED PART AND USE OF A STABILISER COMPOSITION FOR STABILISING TRANSITION-METAL-CONTAINING PLASTICS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2025-02-19 | — | — | EP | claimed |
| US-12226488-B2 | Nitroreductase-releasable pro-drugs and methods for using the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-02-18 | — | — | US | claimed |
| US-20250041194-A1 | COMPOSITION COMPRISING GALACTINOL AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2025-02-06 | — | — | US | claimed |
| CN-119213079-A | Stabilized transition metal-containing plastic compositions, molding compounds or molded parts, and use of stabilizer compositions for stabilizing transition metal-containing plastics | 弗劳恩霍夫应用研究促进协会 | 2024-12-27 | — | — | CN | claimed |
| CN-118401230-A | Composition comprising inositol galactoside and use thereof | 科莱恩国际有限公司 | 2024-07-26 | — | — | CN | claimed |
| WO-2023198777-A1 | STABILISED, TRANSITION-METAL-CONTAINING PLASTICS COMPOSITIONS, MOULDING COMPOUND OR MOULDED PART AND USE OF A STABILISER COMPOSITION FOR STABILISING TRANSITION-METAL-CONTAINING PLASTICS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-10-19 | — | — | WO | claimed |
| EP-4197522-A1 | COMPOSITION COMPRISING GALACTINOL AND USE THEREOF | Clariant International Ltd (CH) | 2023-06-21 | — | — | EP | claimed |
| EP-4076403-A1 | GASTRO-RESISTANT MICROPARTICLES COMPRISING INOSITOL AND/OR GYMNEMA SYLVESTRE EXTRACT, PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | IDI Integratori Dietetici Italiani S.r.l. (IT) | 2022-10-26 | — | — | EP | claimed |
| US-5998485-A | DOSE DEPENDENT | CEDARS-SINAI MEDICAL CENTER (US) | 1999-12-07 | — | — | US | claimed |
| US-5981716-A | Process for the purification of proteins | GRUPPO LEPETTIT, S.P.A. (IT) | 1999-11-09 | — | — | US | claimed |
| WO-1998057620-B1 | INOSITOL FOR MODULATION OF IMMUNE RESPONSE | CEDARS SINAI MEDICAL CENTER (US) | 1999-04-15 | — | — | WO | claimed |
| WO-1998057620-A2 | INOSITOL FOR MODULATION OF IMMUNE RESPONSE | CEDARS-SINAI MEDICAL CENTER (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0820468-A1 | PROCESS FOR THE PURIFICATION OF GLYCOPROTEINS LIKE ERYTHROPOIETIN | GRUPPO LEPETIT S.P.A. (IT) | 1998-01-28 | — | — | EP | claimed |
| WO-1997034853-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 1997-09-25 | — | — | WO | claimed |
| WO-1996032413-A1 | PROCESS FOR THE PURIFICATION OF GLYCOPROTEINS LIKE ERYTHROPOIETIN | GRUPPO LEPETIT S.P.A. (IT) | 1996-10-17 | — | — | WO | claimed |
| EP-0505452-B1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT | PERSTORP AB (SE) | 1996-06-19 | — | — | EP | claimed |
| WO-1995032978-A1 | TRIVALENT METAL COMPLEXES WITH A POLYOL SUCH AS CIS-INOSITOL, FOR MEDICAL USE AND METHOD OF PREPARATION | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1995-12-07 | — | — | WO | claimed |
| EP-0524082-B1 | Process for the preparation of eventually deuterated cis-inositol, meso-inositol, epi-inositol and/or cis-quercitol | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1995-10-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226488-B2 | Nitroreductase-releasable pro-drugs and methods for using the same | AKR1B1, AKR1A1, POR | LMNA 1971/4885APP 3921/4885GBA1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.